Emotional evaluation from patients with delayed and scheduled SCIT.
To investigate the level of anxiety and depression related symptoms in patients undergoing SCIT at V0 and V1, we compared the SAS and SDS data to healthy controls: healthy subjects outside of22 or during23 the COVID-19 outbreak; COVID-19 related individuals (front-line clinical staff24 or survivors25 of COVID-19); patients with allergy and inflammation related diseases (AR26, asthma27, chronic rhinosinusitis (CRS)28); patients with chronic disorders (coronary heart disease (CHD)29, functional dyspepsia (FD)22 and primary insomnia (PI)30); and cancer patients post radiotherapy (RT)31 in China.
As shown in figure 3, A , SAS in patients with delayed SCIT at V1 was 33.79 ± 7.95, which was significantly lower than 40.66 ± 7.61 in the scheduled SCIT group at V0, 37.96 ± 5.23 of healthy control during the COVID-19 outbreak, 45.89 ± 1.12 of front-line clinical staff in the COVID-19 outbreak, 43.2 ± 10.2 of COVID-19 survivors, 42.23 ± 14.32 of AR patients, 40.80 ± 8.10 of asthma patients, 39.4 0 ± 11.55 of CRS patients, 43.9 ± 5.6 of patients with CHD, 42.07 ± 8.01 of patients with FD, 51.8 ± 10.8 of patients with PI, and 55.69 ± 10.01 of cancer patients post RT (all P < 0.0001). However, there was no significant difference between patients with delayed SCIT at V1 (33.79 ± 7.95) when compared to patients with scheduled SCIT at V1 (34.84 ± 7.07), patients with delayed SCIT at V0 (34.87 ± 8.48), or to healthy controls outside of the COVID-19 outbreak (33.85 ± 6.4).
As shown in figure 3, B , the SDS score in delayed SCIT patients at V1 (38.51 ± 12.88) was significantly lower when compared to delayed SCIT patients at V0 (40.48 ± 14.86, P < 0.01), and also scheduled SCIT patients at both V1 (44.67 ± 14.74, P < 0.0001) and V0 (56.13 ± 10.73, P < 0.0001). Similarly, the SDS score in delayed SCIT patients at V1 was not statistically different from the healthy controls outside of the COVID-19 outbreak (34.81 ± 7.43). However, this was dramatically decreased when compared with healthy patients during the COVID-19 outbreak (44.2 ± 5.46), front-line clinical staff in the COVID-19 outbreak (50.13 ± 1.813), COVID-19 survivors (47.3 ± 13.1), patients with AR (43.32 ± 13.78), asthma (44.90 ± 9.10), CRS (54.05 ± 10.96), CHD (53.60 ± 8.70), FD (43.27 ± 10.04), PI (55.40 ± 8.90), and cancer patients post RT (59.05 ± 9.40), all P < 0.05. Among them, scheduled SCIT patients at V1 and V0, delayed SCIT patients at V0, COVID-19 survivors, patients with AR, asthma, CRS, CHD, FD, PI and cancer patients post RT had a SDS scores over the depression threshold of 53.
The proportion of patients without depression from the scheduled and delayed SCIT groups were 28.11% and 66.86% at V0, and 60.95% and 82.12% at V1, respectively. The percentage of; mildly depressed patients for the scheduled and delayed groups was 60.33% and 29.33% at V0, 32.35% and 18.96% at V1; and moderately depressed patients, 11.16% and 3.81% at V0, 5.80% and 1.42% at V1, respectively (all P < 0.0001). Severely depressed patients accounted for 0.40% and 0.90% at V0 and V1 respectively from the scheduled SCIT group, with 0% in the delayed SCIT group at both timepoints (Figure 3, C ). In addition, a positive correlation of SDS and time interval of SCIT delay (r = 0.3975, P < 0.0001) was observed (Figure 3, D ). The proportion of SAS, as well as the correlation between SAS and delayed SCIT time interval at V0 are shown in figure S1 .